Portugal - portugais - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

denk pharma gmbh & co. kg - valsartan + hidroclorotiazida - comprimido revestido por película - 160 mg + 12.5 mg - valsartan 160 mg ; hidroclorotiazida 12.5 mg - valsartan and diuretics - genérico - duração do tratamento: longa duração

Portugal - portugais - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

denk pharma gmbh & co. kg - valsartan + hidroclorotiazida - comprimido revestido por película - 160 mg + 12.5 mg - valsartan 160 mg ; hidroclorotiazida 12.5 mg - valsartan and diuretics - genérico - duração do tratamento: longa duração

Taïwan - chinois - 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

台灣諾華股份有限公司 台北市中山區民生東路三段2號8樓 (01516589) - valsartan - 膜衣錠 - valsartan (2408005100) mg - valsartan - 治療成人和6-18 歲的兒童或青少年高血壓、心衰竭(nyha 二到四級)、心肌梗塞後左心室功能異常。

Taïwan - chinois - 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

瑩碩生技醫藥股份有限公司 台北市中山區南京東路二段206號8樓之3 (80207616) - valsartan;;amlodipine besilate - 膜衣錠 - valsartan (2408005100) mg; amlodipine besilate (2412402220) (eq. to amlodipine.....5mg)mg - valsartan and amlodipine - 治療高血壓，此複方藥品不適用於起始治療。

États-Unis - anglais - NLM (National Library of Medicine)

rebel distributors corp - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 80 mg - diovan® (valsartan) is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. diovan is indicated for the treatment of heart failure (nyha class ii-iv). in a controlled clinical trial, diovan significantly reduced hospitalizations for heart failure. there is no evidence that diovan provides added benefits when it is used with an adequate dose of an ace inhibitor. [ see  clinical studies (14.2)]   in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction, diovan is indicated to reduce cardiovascular mortality. [ see  clinical studies (14.3 ) ] none teratogenic effects: pregnancy category d diovan, like other drugs that act on the renin angiotensin system, can cause fetal and neonatal morbidity and death when used during the second or third trimester of pregnancy. diovan can cause fetal harm when administered to a pregnant woman. if this drug is used during pregnancy, or if the p

Portugal - portugais - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

towa pharmaceutical, s.a. - valsartan + hidroclorotiazida - comprimido revestido por película - 160 mg + 25 mg - valsartan 160 mg ; hidroclorotiazida 25 mg - valsartan and diuretics - genérico - duração do tratamento: longa duração

Portugal - portugais - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

towa pharmaceutical, s.a. - valsartan + hidroclorotiazida - comprimido revestido por película - 160 mg + 25 mg - valsartan 160 mg ; hidroclorotiazida 25 mg - valsartan and diuretics - genérico - duração do tratamento: longa duração

Portugal - portugais - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

towa pharmaceutical, s.a. - valsartan + hidroclorotiazida - comprimido revestido por película - 160 mg + 25 mg - valsartan 160 mg ; hidroclorotiazida 25 mg - valsartan and diuretics - genérico - duração do tratamento: longa duração

Portugal - portugais - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

towa pharmaceutical, s.a. - valsartan + hidroclorotiazida - comprimido revestido por película - 160 mg + 12.5 mg - valsartan 160 mg ; hidroclorotiazida 12.5 mg - valsartan and diuretics - genérico - duração do tratamento: longa duração

États-Unis - anglais - NLM (National Library of Medicine)

physicians total care, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 40 mg - diovan® (valsartan) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with diovan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluati